+86 189 1304 2753 product@eynoslifescience.com

Every entry reports the starting frequency, the format used and what the flow-through contained. Customer samples are anonymised; internal validation is labelled as such.

Product validation 2026-11-19

Product validation | anti-mouse CD19 Nanobeads (PM019): B cells from mouse liver, 87.02% CD45⁺CD19⁺ of live cells

anti-mouse CD19 Nanobeads (PM019) on mouse liver: 8 mice pooled yielded 8x10^6 cells; after column selection 87.02% of live cells were CD45+CD19+, with a gating chain of 96.27% / 89.36% / 91.26% / 87.02%. Includes three practical notes on hepatic B-cell isolation.

Product validation 2026-11-19

Product validation | anti-mouse CD8 Nanobeads (PM008): 13.9% residual CD8⁺ after depletion in mouse thymus, versus 67.5% with the competitor

anti-mouse CD8 Nanobeads (PM008) depleting CD4+CD8+ double-positive cells from mouse thymus: residual CD8+ in the flow-through 13.92% versus 67.50% for the competitor at the same bead dose; positive-selection purity was comparable at 98.95% and 99.53%.

Product validation 2026-11-15

Product validation | anti-human CD66b Nanobeads (PH066B): 55.7% → 99.3% in lysed blood, 88.0% → 99.9% in whole blood

Human peripheral blood separated with anti-human CD66b Nanobeads: CD66b⁺ cells rose from 55.7% to 99.3% after one column in lysed blood; in whole blood CD45⁺ cells went from 15% to 93.5% and CD66b⁺ inside the CD45 gate from 88.0% to 99.9%. One protocol serves both enrichment and depletion, with two documented routes — 11 steps after red-cell lysis or 6 steps on whole blood (manual v26.01).

English summary
Product validation 2026-11-04

Product validation | anti-mouse CD19 Nanobeads (PM019): 55.6% → 94.4% in mouse spleen, 1.54% left in the flow-through

Mouse spleen separated with anti-mouse CD19 Nanobeads: CD19⁺ cells rose from 55.6% to 94.4% after one column, leaving 1.54% in the flow-through, so one protocol covers both enrichment and depletion. Includes the CD19 expression boundary (plasma cells negative, follicular dendritic cells positive), the separation principle, raw flow plots, bead dosing by starting frequency and the seven-step protocol (manual v26.01).

English summary
Product validation 2026-10-24

Product validation | anti-mouse CD49b Nanobeads (PM049B): 3.54% → 87.6% in mouse spleen, 1.28% left in the flow-through

Mouse spleen separated with anti-mouse CD49b Nanobeads: CD49b⁺ cells rose from 3.54% to 87.6% after one column (about 24.7-fold enrichment) with 1.28% remaining in the flow-through, so one protocol covers both enrichment and depletion. Includes the separation principle, raw flow plots, bead dosing, a seven-step protocol and the manual update to v26.02.

English summary
Product validation 2026-10-18

Product validation | anti-mouse CD11c Nanobeads (PM011C), third-party test: 85.5% vs 70.1% for the imported reagent

A parallel split-sample comparison on mouse spleen DCs, acquired to 10,000 events: CD11c⁺ purity reached 85.5% against 70.1% for the imported reference — a 15.4 percentage-point gain (+22% relative). Gates were not pre-gated on CD45; no absolute counts were recorded, so yield is not calculated.

English summary
Product validation 2026-10-16

Product validation | EasyTune™ mouse Th1/Th2 differentiation kits (DM102/DM103): 0.010% → 50.7% and 0.76% → 18.0%

Naive CD4⁺ T cells from C57BL/6J spleen, activated with CD3/CD28 beads and polarised for five days in 48-well plates: CD4⁺IFN-γ⁺ rose from 0.010% to 50.7% with DM102, and CD4⁺IL-4⁺ from 0.76% to 18.0% with DM103. Intracellular staining after permeabilisation; uninduced controls shown alongside.

English summary
Product validation 2026-10-13

Product validation | anti-mouse CD117 Nanobeads (PM117): enrichment and depletion of mouse bone-marrow progenitors

Mouse bone-marrow CD117⁺ cells sit at roughly 10–30% of the suspension. One column gives an enriched fraction for CFU assays or flow sorting, and the flow-through is a ready CD117-depleted counterpart; the manual quotes purity up to 85%. CD117⁺ is a progenitor pool, not a stem-cell definition — LSK is closer to the stem fraction.

English summary
Product validation 2026-09-25

Product validation | Envelope-engineered lentivirus (LVh34/LVh45): 47.4% in the hard-to-transduce KG-1 model

KG-1 is a myeloid line that resists VSV-G pseudotypes. At MOI 50 the engineered envelope raised transduction from 22.8% to 47.4% (about 2.1-fold) under otherwise identical conditions; LVh45 reached 44.1%. A relative comparison inside one cell-line model, not a promise for primary HSC.

English summary
Product validation 2026-09-15

Product validation | anti-human CD8 Nanobeads (PH008): high-purity isolation of CD8⁺ T lymphocytes

Column-based positive selection of human CD8⁺ T cells from PBMC, covering bead dosing, column loading and the purity readout, with notes on panel design when the target antigen itself is the readout.

English summary
Product validation 2026-07-22

Product validation | anti-human CD34 Nanobeads (PH034) in a cell-therapy setting: 0.15% → 45.58% → 86.14%

A rare starting population: CD34⁺ cells at 0.15% reached 45.58% after the first column (about 304-fold) and 86.14% after a second column on a fresh cartridge (about 574-fold). No absolute counts were recorded, so no yield is reported.

English summary
Product validation 2026-07-06

Product validation | anti-mouse CD45 Nanobeads (PM045), third-party test: 8.87% → 95.0%, 0.33% in the flow-through

A single mouse sample separated on a column: CD45⁺ cells went from 8.87% before separation to 95.0% in the positive fraction (10.7-fold, +86.13 pp), with 0.33% residual in the flow-through (96.3% relative depletion). That residual corresponds to about 24 events inside the gate.

English summary
Product validation 2026-07-04

Product validation | anti-human CD34 Nanobeads (PH034) head-to-head with an imported reagent: 87.10% vs 83.54%

Split-sample comparison: fresh PBMC reached 87.10% vs 83.54% for the imported reference (+3.56 pp, +4.26% relative), frozen aliquots 91.43% vs 85.85% (+5.58 pp, +6.50% relative). Both vendors scored higher on frozen material, so purity is not comparable across batches — compare within a batch only.

English summary

9 articles in this section. Every article has an English page — each card opens it, with the same figures and the same caveats.

Looking for the protocol behind one of these results?

Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.